Structural analysis of asunaprevir resistance in HCV NS3/4A protease

ACS Chemical Biology

Volumn 9, Issue 11, 2014, Pages 2485-2490

  Soumana, Djadé I ^a   Ali, Akbar ^a   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR; DANOPREVIR; FALDAPREVIR; MACROCYCLIC COMPOUND; SOVAPREVIR; VANIPREVIR; ANTIVIRUS AGENT; CARRIER PROTEIN; ISOQUINOLINE DERIVATIVE; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A COFACTOR PEPTIDE, HEPATITIS C VIRUS; SULFONAMIDE; VIRUS PROTEIN;

ARTICLE; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG DESIGN; DRUG INTERACTION; DRUG POTENCY; DRUG RESISTANCE; DRUG SENSITIVITY; HEPATITIS C VIRUS; ANTIVIRAL RESISTANCE; CHEMISTRY; DRUG EFFECTS; GENETICS; HEPACIVIRUS;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; CARRIER PROTEINS; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; ISOQUINOLINES; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84914179769     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb5006118     Document Type: Article

References (29)

1. Modi, A. A. and Liang, T. J. (2008) Hepatitis C: a clinical review Oral Diseases 14, 10-14
2. Alter, M. J. (2007) Epidemiology of hepatitis C virus infection World J. Gastroenterol. 13, 2436-2441
3. Kwong, A. D. (2014) The HCV revolution did not happen overnight ACS Med. Chem. Lett. 5, 214-220
4. Chen, Z., Benureau, Y., Rijnbrand, R., Yi, J., Wang, T., Warter, L., Lanford, R. E., Weinman, S. A., Lemon, S. M., Martin, A., and Li, K. (2007) GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS J. Virol. 81, 964-976
5. Li, K., Foy, E., Ferreon, J. C., Nakamura, M., Ferreon, A. C., Ikeda, M., Ray, S. C., Gale, M., Jr., and Lemon, S. M. (2005) Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF Proc. Natl. Acad. Sci. U.S.A. 102, 2992-2997
6. Li, X. D., Sun, L., Seth, R. B., Pineda, G., and Chen, Z. J. (2005) Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity Proc. Natl. Acad. Sci. U.S.A. 102, 17717-17722
7. Kwong, A. D., Kauffman, R. S., Hurter, P., and Mueller, P. (2011) Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus Nat. Biotechnol. 29, 993-1003
8. Rotella, D. P. (2013) The discovery and development of boceprevir Expert Opin. Drug Discovery 8, 1439-1447
9. McPhee, F. (2010) Identification and preclinical profile of the novel HCV NS3 protease inhibitor BMS-650032 J. Hepatol. 52, S296
10. White, P. W., Llinais-Brunet, M., Amad, M. a., Bethell, R. C., Bolger, G., Cordingley, M. G., Duan, J., Garneau, M., Lagacé, L., Thibeault, D., and Kukolj, G. (2010) Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease Antimicrob. Agents Chemother. 54, 4611-4618
11. Seiwert, S. D., Andrews, S. W., Jiang, Y., Serebryany, V., Tan, H., Kossen, K., Rajagopalan, P. T., Misialek, S., Stevens, S. K., Stoycheva, A., Hong, J., Lim, S. R., Qin, X., Rieger, R., Condroski, K. R., Zhang, H., Do, M. G., Lemieux, C., Hingorani, G. P., Hartley, D. P., Josey, J. A., Pan, L., Beigelman, L., and Blatt, L. M. (2008) Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227) Antimicrob. Agents Chemother. 52, 4432-4441
12. Lin, T.-I., Lenz, O., Fanning, G., Verbinnen, T., Delouvroy, F., Scholliers, A., Vermeiren, K., Rosenquist, A., Edlund, M., Samuelsson, B., Vrang, L., de Kock, H., Wigerinck, P., Raboisson, P., and Simmen, K. (2009) In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor Antimicrob. Agents Chemother. 53, 1377-1385
13. Liverton, N. J., Carroll, S. S., DiMuzio, J., Fandozzi, C., Graham, D. J., Hazuda, D., Holloway, M. K., Ludmerer, S. W., McCauley, J. A., McIntyre, C. J., Olsen, D. B., Rudd, M. T., Stahlhut, M., and Vacca, J. P. (2010) MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease Antimicrob. Agents Chemother. 54, 305-311
14. Harper, S., McCauley, J. A., Rudd, M. T., Ferrara, M., DiFilippo, M., Crescenzi, B., Koch, U., Petrocchi, A., Holloway, M. K., Butcher, J. W., Romano, J. J., Bush, K. J., Gilbert, K. F., McIntyre, C. J., Nguyen, K. T., Nizi, E., Carroll, S. S., Ludmerer, S. W., Burlein, C., DiMuzio, J. M., Graham, D. J., McHale, C. M., Stahlhut, M. W., Olsen, D. B., Monteagudo, E., Cianetti, S., Giuliano, C., Pucci, V., Trainor, N., Fandozzi, C. M., Rowley, M., Coleman, P. J., Vacca, J. P., Summa, V., and Liverton, N. J. (2012) Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor ACS Med. Chem. Lett. 3, 332-336
15. Sarrazin, C. and Zeuzem, S. (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138, 447-462
16. Romano, K. P., Ali, A., Royer, W. E., and Schiffer, C. A. (2010) Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding Proc. Natl. Acad. Sci. U.S.A. 107, 20986-20991
17. Ali, A., Aydin, C., Gildemeister, R., Romano, K. P., Cao, H., Ozen, A., Soumana, D., Newton, A., Petropoulos, C. J., Huang, W., and Schiffer, C. A. (2013) Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance ACS Chem. Biol. 8, 1469-1478
18. McPhee, F., Sheaffer, A. K., Friborg, J., Hernandez, D., Falk, P., Zhai, G., Levine, S., Chaniewski, S., Yu, F., Barry, D., Chen, C., Lee, M. S., Mosure, K., Sun, L. Q., Sinz, M., Meanwell, N. A., Colonno, R. J., Knipe, J., and Scola, P. (2012) Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032) Antimicrob. Agents Chemother. 56, 5387-5396
19. McPhee, F., Friborg, J., Levine, S., Chen, C., Falk, P., Yu, F., Hernandez, D., Lee, M. S., Chaniewski, S., Sheaffer, A. K., and Pasquinelli, C. (2012) Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir Antimicrob. Agents Chemother. 56, 3670-3681
20. Everson, G. T., Sims, K. D., Rodriguez-Torres, M., Hézode, C., Lawitz, E., Bourliere, M., Loustaud-Ratti, V., Rustgi, V., Schwartz, H., Tatum, H., Marcellin, P., Pol, S., Thuluvath, P. J., Eley, T., Wang, X., Huang, S.-P., McPhee, F., Wind-Rotolo, M., Chung, E., Pasquinelli, C., Grasela, D. M., and Gardiner, D. F. (2014) Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 Infection Gastroenterology 146, 420-429
21. Romano, K. P., Laine, J. M., Deveau, L. M., Cao, H., Massi, F., and Schiffer, C. A. (2011) Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease J. Virol. 85, 6106-6116
22. Romano, K. P., Ali, A., Aydin, C., Soumana, D., Ozen, A., Deveau, L. M., Silver, C., Cao, H., Newton, A., Petropoulos, C. J., Huang, W., and Schiffer, C. A. (2012) The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors PLoS Pathog. 8, e1002832
23. Manns, M. P., Gane, E., Rodriguez-Torres, M., Stoehr, A., Yeh, C.-T., Marcellin, P., Wiedmann, R. T., Hwang, P. M., Caro, L., Barnard, R. J. O., Lee, A. W., and MK-7009 Protocol 007 Study Group. (2012) Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naieve patients with chronic hepatitis C: A randomized phase II study Hepatology 56, 884-893
24. Manns, M. P., Bourlieare, M., Benhamou, Y., Pol, S., Bonacini, M., Trepo, C., Wright, D., Berg, T., Calleja, J. L., White, P. W., Stern, J. O., Steinmann, G., Yong, C.-L., Kukolj, G., Scherer, J., and Boecher, W. O. (2011) Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection J. Hepatol. 54, 1114-1122
25. Svarovskaia, E. S., Martin, R., McHutchison, J. G., Miller, M. D., and Mo, H. (2012) Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy J. Clin. Microbiol. 50, 3267-3274
26. Cento, V., Mirabelli, C., Salpini, R., Dimonte, S., Artese, A., Costa, G., Mercurio, F., Svicher, V., Parrotta, L., Bertoli, A., Ciotti, M., Di Paolo, D., Sarrecchia, C., Andreoni, M., Alcaro, S., Angelico, M., Perno, C. F., and Ceccherini-Silberstein, F. (2012) HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors PLoS One 7, e39652
27. Scola, P. M., Sun, L. Q., Wang, A. X., Chen, J., Sin, N., Venables, B. L., Sit, S. Y., Chen, Y., Cocuzza, A., Bilder, D. M., D'Andrea, S. V., Zheng, B., Hewawasam, P., Tu, Y., Friborg, J., Falk, P., Hernandez, D., Levine, S., Chen, C., Yu, F., Sheaffer, A. K., Zhai, G., Barry, D., Knipe, J. O., Han, Y. H., Schartman, R., Donoso, M., Mosure, K., Sinz, M. W., Zvyaga, T., Good, A. C., Rajamani, R., Kish, K., Tredup, J., Klei, H. E., Gao, Q., Mueller, L., Colonno, R. J., Grasela, D. M., Adams, S. P., Loy, J., Levesque, P. C., Sun, H., Shi, H., Sun, L., Warner, W., Li, D., Zhu, J., Meanwell, N. A., and McPhee, F. (2014) The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection J. Med. Chem. 57, 1730-1752
28. Oezen, A., Sherman, W., and Schiffer, C. A. (2013) Improving the resistance profile of hepatitis C NS3/4A inhibitors: Dynamic substrate envelope guided design J. Chem. Theory Comput. 9, 5693-5705
29. Prabu-Jeyabalan, M., Nalivaika, E. A., Romano, K., and Schiffer, C. A. (2006) Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate J. Virol. 80, 3607-3616